AR043670A1 - Composicion farmaceutica que contiene lactato y usos de la misma - Google Patents
Composicion farmaceutica que contiene lactato y usos de la mismaInfo
- Publication number
- AR043670A1 AR043670A1 ARP040100933A ARP040100933A AR043670A1 AR 043670 A1 AR043670 A1 AR 043670A1 AR P040100933 A ARP040100933 A AR P040100933A AR P040100933 A ARP040100933 A AR P040100933A AR 043670 A1 AR043670 A1 AR 043670A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition containing
- per liter
- millimoles per
- pharmaceutical composition
- lactate
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 4
- 235000014655 lactic acid Nutrition 0.000 abstract 2
- 239000004310 lactic acid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000014644 Brain disease Diseases 0.000 abstract 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010053159 Organ failure Diseases 0.000 abstract 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009429 distress Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
Abstract
Composición farmacéutica que contiene entre 250 y 2400 milimoles por litro de lactato o ácido láctico, entre 2 y 10 milimoles por litro del catión potasio y optativamente entre 2 y 5 milimoles por litro del catión calcio; uso farmacéutico de esta composición y uso farmacéutico de una composición que contiene una concentración de ácido láctico o lactato que comprende entre 250 y 2400 milimoles por litro. Para el tratamiento de una afección o enfermedad seleccionada del grupo formado por enfermedades cardiovasculares, trastornos cerebrales, insuficiencia de órganos, obesidad, resucitación y distres nemodinámico agudo debido a razones médicas y cirugía.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ID20030213 | 2003-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043670A1 true AR043670A1 (es) | 2005-08-03 |
Family
ID=33397627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100933A AR043670A1 (es) | 2003-05-01 | 2004-03-22 | Composicion farmaceutica que contiene lactato y usos de la misma |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20080125488A1 (es) |
| EP (2) | EP1759695A1 (es) |
| JP (1) | JP5037937B2 (es) |
| KR (1) | KR101076059B1 (es) |
| CN (1) | CN1777416B (es) |
| AR (1) | AR043670A1 (es) |
| AT (1) | ATE340568T1 (es) |
| AU (1) | AU2004233904B2 (es) |
| BR (1) | BRPI0409867A (es) |
| CA (1) | CA2523740C (es) |
| CY (1) | CY1105880T1 (es) |
| DE (1) | DE602004002585T2 (es) |
| DK (1) | DK1617834T3 (es) |
| EA (2) | EA013846B1 (es) |
| ES (1) | ES2274438T3 (es) |
| HK (1) | HK1085942A1 (es) |
| IL (1) | IL171721A (es) |
| MA (1) | MA27845A1 (es) |
| MX (1) | MXPA05011532A (es) |
| MY (1) | MY140382A (es) |
| NO (1) | NO20055652L (es) |
| NZ (1) | NZ543201A (es) |
| PL (1) | PL1617834T3 (es) |
| PT (1) | PT1617834E (es) |
| SG (1) | SG160217A1 (es) |
| SI (1) | SI1617834T1 (es) |
| TN (1) | TNSN05275A1 (es) |
| TW (1) | TWI290045B (es) |
| UA (1) | UA86937C2 (es) |
| WO (1) | WO2004096204A1 (es) |
| ZA (1) | ZA200509684B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007371A4 (en) * | 2006-04-03 | 2009-07-22 | Innogene Kalbiotech Pte Ltd | LACTAT AND CALCIUM-CONTAINED PHARMACEUTICAL COMPOSITION AND ITS USES |
| DK2142186T3 (da) | 2007-03-30 | 2014-08-04 | Laccure Ab | Anvendelse af oligomerer af mælkesyre ved behandling af gynækologiske infektioner |
| WO2010111650A2 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
| CN102497853B (zh) | 2009-03-26 | 2018-03-23 | 普马特里克斯营业公司 | 治疗肺病的干粉配方与方法 |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| WO2012030647A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| CA2812414C (en) | 2010-09-29 | 2020-09-22 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
| WO2012050945A1 (en) | 2010-09-29 | 2012-04-19 | Pulmatrix, Inc. | Cationic dry powders |
| ES2396650B2 (es) * | 2011-07-21 | 2013-07-16 | Universidad Complutense De Madrid | Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal. |
| CN104487075A (zh) | 2012-02-29 | 2015-04-01 | 普马特里克斯公司 | 可吸入干粉剂 |
| CA2872012C (en) | 2012-05-08 | 2017-06-20 | Aeromics, Llc | New methods |
| DK2879524T3 (en) * | 2012-08-01 | 2016-12-12 | Purac Biochem Bv | Laktatpulver and manufacturing method thereof |
| US9557334B2 (en) | 2012-10-25 | 2017-01-31 | Run Them Sweet Llc | Formulations and methods to provide nutrition to human and other patients |
| US9897609B2 (en) | 2012-10-25 | 2018-02-20 | Run Them Sweet, LLC | Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs |
| US9232815B2 (en) | 2012-10-25 | 2016-01-12 | Run Them Sweet, LLC | Blood lactate range targets and nutritional formulations and protocols to support patients |
| EP2754356A1 (en) | 2013-01-15 | 2014-07-16 | Purac Biochem N.V. | Improved nisin production process |
| EP2769630B1 (en) | 2013-02-26 | 2016-04-27 | Purac Biochem N.V. | Improved nisin production process |
| MX2015013845A (es) | 2013-04-01 | 2016-05-09 | Pulmatrix Inc | Polvos secos de tiotropio. |
| WO2015069961A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Novel prodrug salts |
| WO2015182815A1 (ko) * | 2014-05-26 | 2015-12-03 | 한국생명공학연구원 | Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물 |
| PL3481216T5 (pl) | 2016-07-07 | 2024-07-01 | Dsm Ip Assets B.V. | Sposób otrzymywania izolatu białka rzepakowego i otrzymany za jego pomocą izolat białka rzepakowego |
| US10124021B2 (en) * | 2016-12-23 | 2018-11-13 | Andrew L. Gostine | Intravenous fluid |
| EP3920846A4 (en) * | 2019-02-06 | 2022-11-09 | The Board and Trustees of the Leland Stanford Junior University | BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY RESULTS |
| US20230113843A1 (en) * | 2020-01-24 | 2023-04-13 | Daniel Q. Barkey | Compositions and methods for weight loss |
| KR20240134314A (ko) * | 2021-12-16 | 2024-09-09 | 알베올러스 바이오, 인코포레이티드 | 만성 폐 질환의 치료를 위한 흡입가능한 또는 섭취가능한 락트산 조성물 |
| CN116531358A (zh) * | 2023-06-06 | 2023-08-04 | 中国医科大学附属第一医院 | 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5100677A (en) * | 1985-12-18 | 1992-03-31 | Veech Richard L | Fluid therapy with various organic anions |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5248507A (en) * | 1991-05-31 | 1993-09-28 | Board Of Regents, The University Of Texas System | Hypertonic isochloremic formulation for circulatory shock |
| JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
| US5702880A (en) * | 1993-06-04 | 1997-12-30 | Biotime, Inc. | Blood substitute comprising 0-5 mM K+ |
| US6306828B1 (en) * | 1995-04-06 | 2001-10-23 | Baxter International, Inc. | Enantiomerically-enhanced nutritional energy substrates |
| JPH0940554A (ja) * | 1995-08-03 | 1997-02-10 | Nissho Corp | グルタミンを含む輸液及びその製造方法 |
| WO1998008500A1 (en) * | 1996-08-26 | 1998-03-05 | Board Of Regents, The University Of Texas System | Hypertonic arginine compositions and methods |
| US6436444B1 (en) * | 1997-09-26 | 2002-08-20 | Ecolab Inc. | Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection |
| CN1068778C (zh) * | 1998-05-15 | 2001-07-25 | 赵超英 | 救治用的药物组合物及其制备方法 |
| RU2136293C1 (ru) * | 1998-08-04 | 1999-09-10 | Открытое акционерное общество "Биохимик" | Способ получения заменителя плазмы крови |
-
2004
- 2004-03-22 CN CN2004800110612A patent/CN1777416B/zh not_active Expired - Fee Related
- 2004-03-22 SI SI200430136T patent/SI1617834T1/sl unknown
- 2004-03-22 AU AU2004233904A patent/AU2004233904B2/en not_active Ceased
- 2004-03-22 SG SG200717319-8A patent/SG160217A1/en unknown
- 2004-03-22 DK DK04722501T patent/DK1617834T3/da active
- 2004-03-22 US US10/555,196 patent/US20080125488A1/en not_active Abandoned
- 2004-03-22 BR BRPI0409867-6A patent/BRPI0409867A/pt not_active IP Right Cessation
- 2004-03-22 EP EP06121128A patent/EP1759695A1/en not_active Withdrawn
- 2004-03-22 AR ARP040100933A patent/AR043670A1/es not_active Application Discontinuation
- 2004-03-22 MX MXPA05011532A patent/MXPA05011532A/es active IP Right Grant
- 2004-03-22 JP JP2006508059A patent/JP5037937B2/ja not_active Expired - Fee Related
- 2004-03-22 EA EA200801073A patent/EA013846B1/ru not_active IP Right Cessation
- 2004-03-22 ES ES04722501T patent/ES2274438T3/es not_active Expired - Lifetime
- 2004-03-22 WO PCT/SG2004/000066 patent/WO2004096204A1/en active IP Right Grant
- 2004-03-22 PT PT04722501T patent/PT1617834E/pt unknown
- 2004-03-22 PL PL04722501T patent/PL1617834T3/pl unknown
- 2004-03-22 AT AT04722501T patent/ATE340568T1/de active
- 2004-03-22 UA UAA200511417A patent/UA86937C2/ru unknown
- 2004-03-22 NZ NZ543201A patent/NZ543201A/en not_active IP Right Cessation
- 2004-03-22 CA CA2523740A patent/CA2523740C/en not_active Expired - Fee Related
- 2004-03-22 DE DE602004002585T patent/DE602004002585T2/de not_active Expired - Lifetime
- 2004-03-22 EA EA200501675A patent/EA010948B1/ru not_active IP Right Cessation
- 2004-03-22 MY MYPI20040998A patent/MY140382A/en unknown
- 2004-03-22 EP EP04722501A patent/EP1617834B1/en not_active Expired - Lifetime
- 2004-03-23 TW TW093107705A patent/TWI290045B/zh not_active IP Right Cessation
-
2005
- 2005-10-24 TN TNP2005000275A patent/TNSN05275A1/en unknown
- 2005-11-01 KR KR1020057020706A patent/KR101076059B1/ko not_active IP Right Cessation
- 2005-11-01 IL IL171721A patent/IL171721A/en active IP Right Grant
- 2005-11-30 NO NO20055652A patent/NO20055652L/no not_active Application Discontinuation
- 2005-11-30 ZA ZA200509684A patent/ZA200509684B/en unknown
- 2005-12-01 MA MA28632A patent/MA27845A1/fr unknown
-
2006
- 2006-07-24 HK HK06108198A patent/HK1085942A1/xx not_active IP Right Cessation
- 2006-12-21 CY CY20061101847T patent/CY1105880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043670A1 (es) | Composicion farmaceutica que contiene lactato y usos de la misma | |
| ECSP055739A (es) | Anticuerpos de neutralización contra gdf-8, y sus usos | |
| CL2019003924A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485). | |
| AR054139A1 (es) | Formulacion modificada y de liberacion inmediata de esferas de memantina | |
| AR062536A1 (es) | Acilanilidas sustituidas y composicion farmaceutica | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
| CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
| CL2010001123A1 (es) | Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07). | |
| DE122009000036I2 (de) | Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion | |
| AR047719A1 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri | |
| AR060264A1 (es) | Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion | |
| EE05099B1 (et) | Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid | |
| PE20240885A1 (es) | Sales agonistas de sstr4 | |
| NO20070996L (no) | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser | |
| BRPI0414343A (pt) | combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina | |
| AR039977A1 (es) | Composicion a base de diclofenac para el tratamiento topico de afecciones de la cavidad orofaringea | |
| AR045423A1 (es) | Combinaciones de analiticos y antidepresivos | |
| RU2006109966A (ru) | Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных | |
| BRPI0413750A (pt) | uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit | |
| RU2532399C2 (ru) | Способ лечения пародонтита | |
| Hartman et al. | D43 CELL FATE: Hypoxia, Brain-Derived Neurotrophic Factor, And Extracellular Matrix Remodeling In Human Pulmonary Artery Smooth Muscle Cells | |
| Mittal | Intraparenchymal haemorrhage in an elderly patient: case report | |
| RU2004116284A (ru) | Способ обработки костной полости после некрсеквестрэктомии | |
| PL1700597T3 (pl) | Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |